Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
📊
Temel Bulgular & Veri:Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
💡
Sonuç & Katkı:Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2006 Verileri
⚙️Değişkenler:Alan Parametreleri
Abstract
Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
🔖
Bu Makaleye Atıf Yap
KİREMİTÇi, S., SAK, S. D. (2022). Comparative immunohistochemical characteristics of benign and malignant major salivary gland tumors: A retrospective study. The Turkish Journal of Ear Nose and Throat, Cilt: 29 - Sayı: 1, 9–20. https://ajindex.com/articles/597917
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. World Health Organization Classification of Head and Neck Tumours. 4th ed.Lyon: IARC Press; 2017
Sternlicht MD, Barsky SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses 1997;48:37-46 3. Sternlicht MD, Safarians S, Rivera SP, Barsky SH. Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors. Lab Invest 1996;74:781-96
Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine downregulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003;201:562-72
Prasad AR, Savera AT, Gown AM, Zarbo RJ. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med 1999;123:801-6
Ianez RF, Buim ME, Coutinho-Camillo CM, Schultz R, Soares FA, Lourenço SV. Human salivary gland morphogenesis: myoepithelial cell maturation assessed by immunohistochemical markers. Histopathology 2010;57:410-7
Furuse C, Sousa SO, Nunes FD, Magalhães MH, Araújo VC. Myoepithelial cell markers in salivary gland neoplasms. Int J Surg Pathol 2005;13:57-65. 8. de Araújo VC, Altemani A, Furuse C, Martins MT, de Araújo NS. Immunoprofile of reactive salivary myoepithelial cells in intraductal areas of carcinoma ex-pleomorphic adenoma. Oral Oncol 2006;42:1011-6
Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7
Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24
Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-32
Ogawa Y, Toyosawa S, Ishida T, Ijuhin N. Keratin14 immunoreactive cells in pleomorphic adenomasand adenoid cystic carcinomas of salivary glands. Virchows Arch 2000;437:58-68
Iwafuchi H, Mori N, Takahashi T, Yatabe Y.Phenotypic composition of salivary gland tumors: an application of principal [corrected] component analysis to tissue microarray data. Mod Pathol 2004;17:803-10